増井　翔 （マスイ　ショウ）

MASUI Sho

写真a

所属（所属キャンパス）

薬学部 薬学科 統合臨床薬理学講座 （芝共立）

職名

助教
このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 博士（薬学）, 京都大学, 課程, 2023年03月

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 薬剤師, 2019年04月

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series.

    Masuda T, Funakoshi T, Horimatsu T, Yamamoto S, Matsubara T, Masui S, Nakagawa S, Ikemi Y, Yanagita M, Muto M, Terada T, Yonezawa A

    Cancer chemotherapy and pharmacology 2024年03月

    ISSN  0344-5704

  • Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort.

    Kawakami T, Masui S, Onishi A, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Shimada T, Nakagawa S, Matsuda S, Morinobu A, Terada T, Yonezawa A

    Modern rheumatology 2024年03月

    ISSN  1439-7595

  • Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey

    Takayuki Miyamoto, Kazushi Izawa, Sho Masui, Atsue Yamazaki, Yuichi Yamasaki, Tadashi Matsubayashi, Mayuka Shiraki, Hidenori Ohnishi, Junko Yasumura, Kawabe Tomohiro, Takako Miyamae, Tomoyo Matsubara, Naoya Arakawa, Takashi Ishige, Takumi Takizawa, Asami Shimbo, Masaki Shimizu, Naoki Kimura, Yuichi Maeda, Yuta Maruyama, Tomonari Shigemura, Junichi Furuta, Satoshi Sato, Hiroshi Tanaka, Miharu Izumikawa, Masahiro Yamamura, Toshio Hasegawa, Hiroshi Kaneko, Yasuo Nakagishi, Naoko Nakano, Yasunori Iida, Tamaki Nakamura, Hiroyuki Wakiguchi, Takayuki Hoshina, Toshinao Kawai, Kosaku Murakami, Shuji Akizuki, Akio Morinobu, Koichiro Ohmura, Katsuhide Eguchi, Motoshi Sonoda, Masataka Ishimura, Kenji Furuno, Momoko Kashiwado, Masaaki Mori, Kimito Kawahata, Koremasa Hayama, Kumiko Shimoyama, Natsuko Sasaki, Taisuke Ito, Hiroaki Umebayashi, Tae Omori, Seiko Nakamichi, Tomotsune Dohmoto, Yasuyuki Hasegawa, Hisashi Kawashima, Shojiro Watanabe, Yuichiro Taguchi, Haruna Nakaseko, Naomi Iwata, Hiroki Kohno, Taiki Ando, Yasuhiko Ito, Yuko Kataoka, Takako Saeki, Utako Kaneko, Ayako Murase, Seira Hattori, Tomo Nozawa, Kenichi Nishimura, Reiji Nakano, Misa Watanabe, Masato Yashiro, Tomonori Nakamura, Toshihiko Komai, Kentaro Kato, Yoshitaka Honda, Eitaro Hiejima, Atsushi Yonezawa, Kazuhisa Bessho, Satoshi Okada, Osamu Ohara, Junko Takita, Takahiro Yasumi, Ryuta Nishikomori; Japan CAPS working group

    Arthritis Rheumatol 2024年01月

    研究論文（学術雑誌）, 共著, 査読有り

  • Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.

    Masui S, Yonezawa A, Nakamura M, Onishi A, Hashimoto M, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Yokoyama K, Iwamoto N, Shimada T, Itohara K, Hira D, Nakagawa S, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K

    Biological & pharmaceutical bulletin （Biological and Pharmaceutical Bulletin）  46 （ 8 ） 1112 - 1119 2023年

    研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  0918-6158

    　概要を見る

    Secondary non-response to infliximab (IFX) occurs in some patients with rheumatoid arthritis (RA). Although therapeutic drug monitoring (TDM) is a useful tool to optimize IFX therapy, it is unclear whether it can help to identify the risk of secondary non-response. This study aimed to explore the utility of serum levels of IFX or other biomarkers to predict IFX discontinuation owing to secondary non-response. A single-center, retrospective study was conducted using the Kyoto University Rheumatoid Arthritis Management Alliance cohort database between 2011 and 2020. Serum IFX levels were measured using liquid chromatography-tandem mass spectrometry. An electrochemiluminescence assay was used to quantify serum levels of tumor necrosis factor-α and interleukin-6 and detect anti-drug antibodies. Eighty-four out of 310 patients were eligible for this study. The cutoff levels of biomarkers were determined by receiver operating characteristic analysis. IFX persistence was similar between groups stratified using IFX levels, tumor necrosis factor-α levels, interleukin-6 levels, and anti-drug antibodies positivity. The group with lower IFX and higher interleukin-6 levels had the worst therapy persistence (p=0.017) and the most frequent disease worsening (90.0%, p<0.001). Evaluating both interleukin-6 and IFX levels, not just IFX alone, enabled us to identify patients at risk of discontinuing IFX treatment. These findings support the utility of measuring IFX and interleukin-6 levels for successful maintenance therapy for RA.

  • N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4.

    Masui S, Yonezawa A, Yokoyama K, Iwamoto N, Shimada T, Onishi A, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Nakagawa S, Hira D, Itohara K, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K

    Pharmaceutical research （Pharmaceutical Research）  39 （ 10 ） 2541 - 2554 2022年10月

    研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  0724-8741

    　概要を見る

    Purpose: Biologics are structurally heterogeneous and can undergo biotransformation in the body. Etanercept (ETN) is a fusion protein composed of a soluble tumor necrosis factor (TNF) receptor and the Fc portion of human immunoglobulin G1. The N-terminus of ETN has a putative sequence cleaved by dipeptidyl peptidase-4 (DPP-4). The purpose of this study was to investigate the biotransformation of ETN in humans and mice and evaluate its effects on functional properties. Methods: An analytical method using liquid chromatography-mass spectrometry (LC–MS/MS) was established. The N-terminal heterogeneity of ETN was assessed in the serum of patients with rheumatoid arthritis or mice receiving ETN. The in vitro N-terminal truncation was explored using recombinant DPP-4. The binding affinity to TNF-α or TNF-β was investigated using an in-house enzyme-linked immunosorbent assay. Results: In the formulations, about 90% of ETN had an intact N-terminus, while the N-terminal truncated form was most abundant in the serum of the patients with rheumatoid arthritis and mice. Recombinant human DPP-4 cleaved two amino acids from the N-terminus of ETN in vitro. Sitagliptin, a DPP-4 inhibitor, inhibited N-terminal truncation both in vivo and in vitro. However, N-terminal truncation did not affect the binding ability to TNF-α or TNF-β and the pharmacokinetics of ETN. ETN biosimilars exhibited similar characteristics to the reference product in vivo and in vitro. Conclusions: ETN undergoes N-terminal truncation in the body, and DPP-4 cleaves exogenous ETN via N-terminal proteolysis. The application of an MS-based assay will detect novel biotransformation of therapeutic proteins.

全件表示 >>

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • 血中インフリキシマブおよびインターロイキン６濃度の測定は関節リウマチ患者のインフリキシマブ治療の継続予測に有用である

    増井 翔,中村 美由紀,大西 輝,橋本 求,鬼澤 秀夫,藤井 貴之,村上 孝作,村田 浩一,田中 真生,横山 琴子,岩本 典子,嶋田 崇史,糸原 光太郎,平 大樹,中川 俊作,今井 哲司,中川 貴之,早狩 誠,松田 秀一,森信 暁雄,寺田 智祐,松原 和夫,米澤 淳

    日本薬学会第144回年会, 

    2024年03月
    , 

    口頭発表（一般）

  • バイオシミラーと先行品を用いた抗エタネルセプト抗体測定法の比較

    中山 葵,増井 翔,津田 真弘, 寺田 智祐,米澤 淳

    第17回次世代を担う若手のための医療薬科学シンポジウム, 

    2023年09月
    , 

    口頭発表（一般）

  • インフリキシマブのバイオトランスフォーメーションと薬理活性に与える影響

    島田美緒, 米澤淳, 増井翔, 横山琴子, 嶋田崇史, 橋井則貴, 石井明子, 今吉菜月, 津田真弘, 寺田智祐

    医療療薬学フォーラム 2023 第 31 回クリニカルファーマシーシンポジウム, 

    2023年07月
    , 

    ポスター発表

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 抗体医薬インフリキシマブの生体内構造変化解析に基づくPK・PD変動評価

    2024年04月
    -
    2027年03月

    増井 翔, 若手研究, 補助金,  研究代表者

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 課題研究（統合臨床薬理学）

    2024年度

  • 演習（統合臨床薬理学）

    2024年度

  • 卒業研究１（薬学科）

    2024年度

  • 実務実習事前学習（実習）

    2024年度

  • 英語演習（薬学科）

    2024年度

全件表示 >>

このページの先頭へ▲